Mark Levy, one of the co-editors of this blog, will be on a panel discussing “Machine Learning, AI, and Digital Health” as part of the Food and Drug Law Institute’s Annual Conference in Washington, D.C., on May 2-3.
The panel will focus on digital health technologies, which are rapidly integrating into healthcare and life sciences – from wearables in clinical trials to digital tools for disease management and clinical decision support. Many of these technologies are and will deploy machine learning and artificial intelligence. This panel will discuss how these new technologies are being integrated and how FDA’s role in regulation will continue to evolve. FDA’s recent discussion paper on AI devices, as well as the challenges of AI regulation generally, such as liability, quality assurance, and approval pathways for a product that continually evolves will also be discussed.
Sign up with the discount code annual15 for a 15% discount on registration, and learn more at fdli.org/annual.